MedTrace Logo

Zephyr Etude Post-Inscription (French Registry)

NCT04517916 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 155

Last updated 2026-02-18

No results posted yet for this study

Summary

The objective of this Registry is to provide ongoing safety and effectiveness assessment of the Zephyr Valve treatment of adult patients with Chronic Obstructive Pulmonary Disease (COPD) Grade III and Grade IV in order to support the renewal of the inscription of the Zephyr Valve on the list LPPR (Art 165-1) in France.

Conditions

  • Emphysema or COPD

Interventions

DEVICE

Zephyr Valve

Subjects prescribed Zephyr Valve treatment for their emphysema/COPD and treated with the Zephyr Valves.

Sponsors & Collaborators

  • Pulmonx Corporation

    lead INDUSTRY

Principal Investigators

  • Thomas Egenod, MD · Hôpital Dupuytren (CHRU Limoges)

  • Dennis McHugh · Pulmonx Corporation

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-04
Primary Completion
2022-06-22
Completion
2026-01-28

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04517916 on ClinicalTrials.gov